SG Americas Securities
NVIV

SG Americas Securities’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

SG Americas Securities’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$143K – 3209
2016
Q1 		$143K Buy
+1
New +$107K ﹤0.01% 2400

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

SG Americas Securities's NVIV Position: Q2 2016 in Review

SG Americas Securities sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2016, closing a stake of 1 share — an estimated $143K sold.

SG Americas Securities first reported a position in NVIV in Q1 2016 and held it in 1 quarter. The position peaked at $143K in Q1 2016. 44 funds tracked by Wall St. Rank hold NVIV as of Q2 2016.

  • SG Americas Securities reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2016 after selling out during the quarter.
  • SG Americas Securities sold 1 InVivo Therapeutics Holdings Corp share in Q2 2016, an estimated $143K.
  • SG Americas Securities first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 1 quarter.
  • SG Americas Securities's InVivo Therapeutics Holdings Corp position peaked at $143K in Q1 2016.
  • 44 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2016.

Based on SG Americas Securities's 13F filing for Q2 2016, filed 3 Aug 2016.